Generic placeholder image

Current Pharmaceutical Biotechnology

Author(s): Gbadebo J. Oyedeji, Charles Adeyemo, Affolabi Dissou, Tope Abiodun, Oyebode A.T. Alli, Olakunle J. Onaolapo, Adejoke Y. Onaolapo, Yemisi Adesiji and Olugbenga A. Olowe*

DOI: 10.2174/1389201021666200226100242

DownloadDownload PDF Flyer Cite As
Prevalence of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients Attending Chest Clinics in Osun-State, Nigeria

Page: [939 - 947] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Background: The development of multidrug-resistant tuberculosis (MDR-TB) poses a considerable threat to tuberculosis control programmes in Nigeria. There is an increase in the prevalence of MDR-TB worldwide both among new tuberculosis cases as well as previously-treated ones. There is also a rise in transmission of resistant strains due to an increase in MDR-TB patients largely due to the poor drug compliance and the impact of Human immunodeficiency virus infection. Therefore, we intend to determine the extent of MDR-TB among attendees of chest clinics in Osun-State, Nigeria.

Objectives: The objective of this study was to determine the prevalence of MDR-TB among confirmed tuberculosis patients attending chest clinics in Osun-State, Nigeria.

Methods: This study was conducted among 207 attendees of chest clinics in Osun-State between June, 2015 and October 15, 2016. Sputum and blood samples of the participants were collected. GeneXpert test was carried out first on the samples for simultaneous identification of MTB and rifampicin resistance. Sputum samples were cultured on Lowenstein-Jensen (L-J) medium using N-acetyl-Lcysteine- sodium hydroxide (NALC-NaOH) decontamination method. Drug susceptibility testing (DST) to three first-line drugs was carried out using the proportion DST method.

Results: The prevalence of MTB was found to be 27.5% while the prevalence of MDR-TB from the fifty-seven isolates was 10.5%. Previously treated and new cases had a prevalence of 7.0% and 3.5% MDR-TB, respectively. Seventy (33.8%) participants were positive for HIV infection, out of which twenty-six (12.6%) had co-infection of tuberculosis and HIV. The mono-resistance rates of the three first-line drugs used were: 5.3% and 8.7% for ethambutol (EMB) and isoniazid (INH), respectively. No isolate had mono-resistance (0%) to rifampicin (RIF).

Conclusion: This study observed the prevalence of 27.5% MTB and a prevalence of 10.5% MDR-TB among the MTB isolates. The prevalence of TB is high in Osun State. MDR-TB prevalence is higher compared with the national estimate of MDR-TB (5.1%) of 2017. Resistant TB is a threat to national tuberculosis control and it is recommended that all the facilities be equipped to cater to its diagnosis.

Keywords: Antituberculous drugs, Bacteria, Chest Clinics, GeneXpert, Pulmonology, Mycobacterium.

Graphical Abstract

[1]
Derseh, D.; Moges, F.; Tessema, B. Smear positive pulmonary tuberculosis and associated risk factors among tuberculosis suspects attending spiritual holy water sites in Northwest Ethiopia. BMC Infect. Dis., 2017, 17(1), 100.
[http://dx.doi.org/10.1186/s12879-017-2211-5] [PMID: 28125981]
[2]
CDC Drug-Resistant TB/TB/CDC https://www.cdc.gov/tb/topic/drtb/default.htm
[3]
Musa, B.M.; Adamu, A.L.; Galadanci, N.A.; Zubayr, B.; Odoh, C.N.; Aliyu, M.H. Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One, 2017, 12(9), e0185105.
[http://dx.doi.org/10.1371/journal.pone.0185105] [PMID: 28945771]
[4]
Global tuberculosis report 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/tb/publications/global_report/en/
[5]
Implementing the End Tb Strategy The Essentials. World Health Organization, 2015. Retrieved: 12.03. 2018 Available at, http://www.who.int/tb/publications/2015/end_tb_essential.pdf?ua=1
[6]
Nigerian Tuberculosis Profile population, 2017.https://extranet.who.int/sree/Reports?op=Replet...HQ.../TB country profile
[7]
Tabassum, M.N.; Khan, M.A.; Afzal, S.; Gilani, S.A.; Gureja, A.W.; Tabassum, S. Determination of Risk Factors among Multi-Drug Resistant Tuberculosis Patients. Annals of King Edward Medical University, 2018, 24, 787-796.
[8]
Manaswini, J; Surya, N.R; Avinash, S. In silico discovery of potential drug molecules to improve the treatment of isoniazid-resistant Mycobacterium tuberculosis, 2018.
[9]
David, H.L. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol., 1970, 20(5), 810-814.
[http://dx.doi.org/10.1128/AEM.20.5.810-814.1970] [PMID: 4991927]
[10]
Mohammed, H.B.; Faheem, M.I.; Maqbool, I.A.D.; Hafiz, M.S.I. Advances in the Treatment Options Towards Drug-Resistant Tuberculosis ISI Thomson -. Int. J. Pharmacol., 2017.
[11]
van der Werf, M.J.; Langendam, M.W.; Huitric, E.; Manissero, D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur. Respir. J., 2012, 39(6), 1511-1519.
[http://dx.doi.org/10.1183/09031936.00125711] [PMID: 22005918]
[12]
Duan, Q.; Chen, Z.; Chen, C.; Zhang, Z.; Lu, Z.; Yang, Y.; Zhang, L. The Prevalence of drug resistant tuberculosis in mainland China:an updated systematic review and meta-analysis. PLoS One, 2016, 11(2), e0148041.
[http://dx.doi.org/10.1371/journal.pone.0148041] [PMID: 26859846]
[13]
World Health Organization Guidelines for surveillance of drug resistance in tuberculosis, 5th ed; World Health Organization: Geneva, 2015.
[14]
world health organization; who. global tuberculosis report. 2017.http://www.who.int/tb/publications/global_report/en/2018
[15]
Solima, M.A. Sabeel, Mohamed Ahmed Salih, ManasikAli, Salah-Eldin EL-Zaki, Nadir Abuzeid, Zeinab Abubaker Mohammed Elgadi, Hisham N. Altayb, Asrar M. A. Elegail, Nuha Y. Ibrahim, and Bahaeldin K. Elamin Phenotypic and Genotypic Analysis of Multidrug-Resistant Mycobacterium tuberculosis Isolates from Sudanese Patients. Tuberc. Res. Treat., 2017, 8340746, 6.
[http://dx.doi.org/10.1155/2017/8340746]
[16]
David, A.J.; Moore, N. Sarita Shah. Alternative methods of diagnosing drug resistance—what can they do for me? J. Infect. Dis., 2011, 204, S1110-S1119.
[http://dx.doi.org/10.1093/infdis/jir448]
[17]
World Health Organisation Global Tuberculosis Control: WHO report 2016; World Health Organisation: Geneva, Switzerland, 2016.
[18]
Kalo, D.; Kant, S.; Srivastava, K.; Sharma, A.K. Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases. Lung India, 2015, 32(4), 339-341.
[http://dx.doi.org/10.4103/0970-2113.159561] [PMID: 26180382]
[19]
In: World Health Organization; Roadmap for Rolling Out Xpert MTB/RIF for Rapid Diagnosis of TB and MDR-TB: Geneva, Switzerland, 2010.
[20]
WHO Technical Guide on NGS for DR-TB Christopher Gilpin. WEBINAR, 2019, 1, 5.
[21]
Barnard, M. N.C.; Gey van Pittius, P. D.; van Helden, M.; Bosman, ; Coetzee, R.M.W. The Diagnostic Performance of the GenoTypeMTBDRplus Version 2 Line Probe Assay Is Equivalent to That of the Xpert MTB/RIF Assay. J. Clin. Microbiol., 2012, 50, 3712-3716.
[http://dx.doi.org/10.1128/JCM.01958-12] [PMID: 22972826]
[22]
Canetti, G.; Fox, W.; Khomenko, A.; Mahler, H.T.; Menon, N.K.; Mitchison, D.A.; Rist, N.; Smelev, N.A. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. World Health Organ., 1969, 41(1), 21-43.
[PMID: 5309084]
[23]
Umeh, E.U.; Ishaleku, D.; Hieukwuemere, C.C. HIV/TB coinfection among patients attending a referral chest clinic in Nasarawa State, Nigeria. J. Appl. Sci. (Faisalabad), 2007, 7, 933-935.
[http://dx.doi.org/10.3923/jas.2007.933.935]
[24]
Mary, E.K.; Jonah, B.O.; Ekerette, E.E. UdemeIta U. Prevalence of tuberculosis in Calabar, Nigeria: A case study of patients attending the outpatients Department of Dr. Lawrence Henshaw Memorial Hospital, Calabar: Saudi. J. Health Sci., 2016, 5, 130-133.
[25]
Nwachukwu, N.C.; Orji, A.; Kanu, I.; Okereke, H.C. Epidemiology of pulmonary tuberculosis in some parts of Abia State, Federal Republic of Nigeria. Asian J. Epidemiol., 2009, 2, 13-19.
[http://dx.doi.org/10.3923/aje.2009.13.19]
[26]
Imam, T.S.; Oyeyi, T.I. A retrospective study of pulmonary tuberculosis (PTB)prevalence amongst patients attending Infectious Diseases Hospital (IDH) in Kano, Nigeria. Bayero J. Pure Appl. Sci., 2008, 1, 10-15.
[27]
Onubogu, C.C.; Kunle-Ope, C.N.; Onyejepu, N.; Nwokoye, N.N.; Raheem, T.Y.; Igbasi, U.T.; Tochukwu, N.E.; Omoloye, R.M.; Ejezie, C.O.; Musa, A.Z.; Odunukwe, N.N.; Onwujekwe, D.I.; Idigbe, E.O. Prevalence of tuberculosis and human immunodeficiency virus (TB/HIV) co-infections amongst patients with bronchopulmonary disorders in Lagos. Afr. J. Microbiol. Res., 2010, 4, 1904-1908.
[28]
Girum, T.; Muktar, E.; Lentiro, K.; Wondiye, H.; Shewangizaw, M. Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop. Dis. Travel Med. Vaccines, 2018, 4, 5.
[http://dx.doi.org/10.1186/s40794-018-0065-5] [PMID: 29942536]
[29]
Eker, B.; Ortmann, J.; Migliori, G.B.; Sotgiu, G.; Muetterlein, R.; Centis, R.; Hoffmann, H.; Kirsten, D.; Schaberg, T.; Ruesch-Gerdes, S.; Lange, C. German TBNET Group Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg. Infect. Dis., 2008, 14(11), 1700-1706.
[http://dx.doi.org/10.3201/eid1411.080729] [PMID: 18976552]
[30]
Otokunefor, K. Otokunefor, TV; Omakwele G. Multi-drug resistant Mycobacterium tuberculosis in Port Harcourt, Nigeria. Afr. J. Lab. Med., 2018, 7, a944.https://ajlmonline.org/index.php/ajlm/article/view/805/1214
[http://dx.doi.org/10.4102/ajlm.v7i2.805]
[31]
Uzoewulu, N.G.; Ibeh, I.N.; Lawson, L.; Goyal, M.; Umenyonu, N. Drug resistant Mycobacterium tuberculosis in Tertiary Hospital South East, Nigeria. J. Med. Microb. Diagn., 2014, 3, 141.
[http://dx.doi.org/10.4172/2161-0703.1000141]
[32]
Ebuenyi, I.D. Prevalence of rifampicin resistance by automated Genexpert rifampicin assay in patients with pulmonary tuberculosis in Yenagoa, Nigeria. Pan Afr. Med. J., 2018, 29, 204.
[http://dx.doi.org/10.11604/pamj.2018.29.204.14579.]
[33]
Badri, M.; Wilson, D.; Wood, R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: A cohort study. Lancet, 2002, 359(9323), 2059-2064.
[http://dx.doi.org/10.1016/S0140-6736(02)08904-3] [PMID: 12086758]
[34]
Viegas, S.O.; Machado, A.; Groenheit, R.; Ghebremichael, S.; Pennhag, A.; Gudo, P.S.; Cuna, Z.; Miotto, P.; Hill, V.; Marrufo, T.; Cirillo, D.M.; Rastogi, N.; Källenius, G.; Koivula, T. Molecular diversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mozambique. BMC Microbiol., 2010, 10, 195.http//www.biomedcentral.com/147-2180/10/195
[http://dx.doi.org/ 10.1186/1471-2180-10-195] [PMID: 20663126]
[35]
Otu, A.; Umoh, V.; Habib, A.; Ameh, S.; Lawson, L.; Ansa, V. Drug Resistance among Pulmonary Tuberculosis Patients in Calabar, Nigeria. Pulm. Med., 2013.2013235190
[http://dx.doi.org/10.1155/2013/235190] [PMID: 24078872]
[36]
Lawson, L.; Habib, A.G.; Okobi, M.I.; Idiong, D.; Olajide, I.; Emenyonu, N.; Onuoha, N.; Cuevas, L.E.; Ogiri, S.O. Pilot study on multidrug resistant tuberculosis in Nigeria. ann. afr. med., 2010, 9(3), 184-187.http://www.annalsafrmed.org/text.asp?2010/9/3/184/68355
[http://dx.doi.org/10.4103/1596-3519.68355 ] [PMID: 20710112]
[37]
Pereira, M.; Tripathy, S.; Inamdar, V.; Ramesh, K.; Bhavsar, M.; Date, A.; Iyyer, R.; Acchammachary, A.; Mehendale, S.; Risbud, A. Drug resistance pattern of Mycobacterium tuberculosis in seropositive and seronegative HIV-TB patients in Pune, India. Indian J. Med. Res., 2005, 121(4), 235-239.
[PMID: 15817941]
[38]
Anastasis, D.; Pillai, G.; Rambiritch, V.; Abdool Karim, S.S. A retrospective study of human immunodeficiency virus infection and drug-resistant tuberculosis in Durban, South Africa. Int. J. Tuberc. Lung Dis., 1997, 1(3), 220-224.
[PMID: 9432367]
[39]
Post, F.A.; Wood, R. HIV infection is not associated with an increased rate of drug-resistant tuberculosis. S. Afr. Med. J., 1997, 87(7), 903.
[PMID: 9259732]
[40]
Siddiqi, S.H.; Hawkins, J.E.; Laszlo, A. Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods. J. Clin. Microbiol., 1985, 22(6), 919-923.
[http://dx.doi.org/10.1128/JCM.22.6.919-923.1985] [PMID: 3934209]
[41]
World Health Organization Gender and Tuberculosis, fact sheet, 2002.
[42]
Lawson, L.; Yassin, M.A.; Abdurrahman, S.T.; Parry, C.M.; Dacombe, R.; Sogaolu, O.M.; Ebisike, J.N.; Uzoewulu, G.N.; Lawson, L.O.; Emenyonu, N.; Ouoha, J.O.; David, J.S.; Davies, P.D.; Cuevas, L.E. Resistance to first-line tuberculosis drugs in three cities of Nigeria. Trop. Med. Int. Health, 2011, 16(8), 974-980.
[http://dx.doi.org/10.1111/j.1365-3156.2011.02792.x] [PMID: 21564425]
[43]
Rifat, M.; Milton, A.H.; Hall, J.; Oldmeadow, C.; Islam, M.A.; Husain, A.; Akhanda, M.W.; Siddiquea, B.N. Development of multidrug resistant tuberculosis in Bangladesh: a case-control study on risk factors. PLoS One, 2014, 9(8), e105214.
[http://dx.doi.org/10.1371/journal.pone.0105214] [PMID: 25136966]
[44]
Law, W.S.; Yew, W.W.; Chiu Leung, C.; Kam, K.M.; Tam, C.M.; Chan, C.K.; Leung, C.C. Risk factors for multidrug-resistant tuberculosis in Hong Kong. Int. J. Tuberc. Lung Dis., 2008, 12(9), 1065-1070.
[PMID: 18713506]
[45]
Smith, S.E.; Pratt, R.; Trieu, L.; Barry, P.M.; Thai, D.T.; Ahuja, S.D.; Shah, S. Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993-2014. Clin. Infect. Dis., 2017, 65(9), 1437-1443.
[http://dx.doi.org/10.1093/cid/cix561] [PMID: 28633501]
[46]
Dubrovina, I.; Miskinis, K.; Lyepshina, S.; Yann, Y.; Hoffmann, H.; Zaleskis, R.; Nunn, P.; Zignol, M. Drug-resistant tuberculosis and HIV in Ukraine: A threatening convergence of two epidemics? Int. J. Tuberc. Lung Dis., 2008, 12(7), 756-762.
[PMID: 18544200]